Quantum BioPharma says it has entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 Lucid-MS clinical trial for multiple sclerosis. The companies say the arrangement is intended to support the trial start-up and conduct for “Lucid-21-302” (Lucid-MS).

Both outlets describe the trial design as a randomized, double-blind, placebo-controlled Phase 2 study of Quantum BioPharma’s novel neuroprotective therapy, TORONTO, Oct. 6, 2026 (Globe Newswire is cited in the announcement). Financial Post frames the announcement as a strategic collaboration with a leading contract research organization, while BNN Bloomberg focuses on the specific Study Start-Up Agreement structure with Thermo Fisher’s clinical research unit. Neither source provides additional results, enrollment figures, or trial timelines beyond the plan to implement the Phase 2 study.

The reporting agrees on the identity of the companies involved, the trial name and target indication (MS), and the key elements of the study’s randomized, double-blind, placebo-controlled Phase 2 design.